Analyst picks & changes
Analysts had mixed reactions to Amylin Pharmaceuticals Inc.'s Phase II data, but most maintained "buy" recommendations. The data showed significant smoothing of post-meal glucose, but failed to show inhibition of hypoglycemia in an insulin challenge. (For the data, see BioCentury, June 13, 1994)
Timothy Wilson of Hambrecht & Quist maintained his "buy," saying he was encouraged by the data on glucose smoothing, and that the market's negative reaction was unwarranted.
In a Phase III study, Wilson said, it is reasonable to predict that tripro-amylin could decrease hemoglobin A1c (HbA1c), a